

RARE CANCERS

50% OF PEOPLE WITH CANCER FIGHT A RARE FORM OF CANCER

According to the National Institutes of Health (NIH), a rare cancer is one typically with a prevalence of fewer than 200,000 affected individuals in the United States. However, half of all patients are battling a cancer classified as rare, making them collectively more common than the term “rare” implies.

Cycle for Survival is the only event dedicated to raising money solely for rare cancer research. Participants and donors make a tangible impact on patients’ lives by funding research studies and clinical trials that result in much-needed and improved treatments.

Every dollar raised goes directly to Memorial Sloan Kettering Cancer Center to fund the fight. Cycle for Survival has contributed to over 100 clinical trials, studies and transformative research initiatives.

»»» FACTS ABOUT RARE CANCERS

- 50% of all cancer diagnoses are classified as “rare”
- All pediatric cancers are “rare”
- Among cancers classified as “rare” are well-known forms of the disease, including: pancreatic cancer, ovarian cancer, cervical cancer, brain cancer, thyroid cancer, sarcoma, leukemia, lymphoma, and many more.

»»» THE CHALLENGE

Rare cancer research is often drastically underfunded. In general, there are fewer treatment options for patients with rare cancers because funding for drug development often lags behind more commercially-viable therapies. With less resources devoted to understanding and treating these diseases, patients face uncertain futures—Cycle for Survival aims to change that.

»»» WHY MEMORIAL SLOAN KETTERING CANCER CENTER

Cycle for Survival is proud to be a part of Memorial Sloan Kettering Cancer Center (MSKCC). Founded in 1884, MSKCC is the world’s oldest and largest private institution dedicated exclusively to the care, control, and cure of cancer. Its legacy of innovation is unparalleled: MSKCC has produced more FDA-approved drugs for the treatment of cancer than any other single academic institution. The Center also treats over 400 subtypes of cancer each year, and is proud to count many of the world’s most renowned leaders in rare cancer research and care among its staff.